If approved, Eyenovia will have the first microdosed
treatment for progressive myopia in the United States.
Prevention of Myopia Progression
MicroPineTM is our proprietary microdose formulation of atropine and product candidate for the prevention of progressive myopia (nearsightedness) in children. Moderate-to-severe myopia is associated with a change to the shape of the eye. This change can lead to significant back-of-the eye problems, including retinal detachment, choroidal and retinal atrophy, and choroidal neovascularization, all of which can lead to permanent vision loss. 1. In the US alone, there are approximately 5 million children with myopia and many times more that number in Asia.
We believe Eyenovia’s delivery technology is particularly well-suited for this application, potentially enabling children to easily self-administer medication while minimizing dose-related side effects.
1. Theophanous, Christos et al. “Myopia prevalence and risk factors in children.” Clinical ophthalmology (Auckland, N.Z.) vol. 12 1581-1587. 29 Aug. 2018, doi:10.2147/OPTH.S164641.
Watch his nighttime routine
Low-dose Atropine and Myopia Progression
There is clinical evidence for the use of low-dose atropine as a way to prevent progressive myopia in children.2 At Eyenovia, we believe that microdosed atropine could provide similar efficacy, while our Optejet™ dispenser could provide additional usability, safety, tolerability and compliance benefits for children.
2. Chua, W., Balakrishnan, V., Chan, Y., Tong, L., Ling, Y., Quah, B., & Tan, D. (2006). Atropine for the Treatment of Childhood Myopia. Ophthalmology, 113(12), 2285-2291. doi:10.1016/j.ophtha.2006.05.062.